Navigation Links
Surveyed Physicians Indicate that Xtandi is Prescribed to Nearly One Quarter of Metastatic Castrate-Resistant Prostate Cancer Patients Who Have Failed to Respond to Prior Docetaxel Treatment
Date:5/6/2013

EXTON, Pa., May 6, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, at six months following launch of Xtandi (Astellas Pharma/Medivation's enzalutamide), surveyed urologists and medical oncologists prescribed Xtandi to a respective 19 percent and 24 percent of their metastatic castrate-resistant prostate cancer (mCRPC) patients who have failed to respond or had very rapid progression from docetaxel (Sanofi's Taxotere, generics) treatment. In six months' time, surveyed respondents expect to prescribe Xtandi to 35-39 percent of these mCRPC patients, making Xtandi the patient share leader in this patient population.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO )

The second wave of the LaunchTrends®: Xtandi report series, fielded six months following the launch of Xtandi in the United States, finds that 30 percent of surveyed urologists have prescribed Xtandi in clinical practice compared with 43 percent of surveyed medical oncologists. In contrast, data published just one month post launch of Xtandi revealed that less than 10 percent surveyed urologists had prescribed Xtandi in clinical practice (i.e., outside of clinical trials), compared with 39 percent of their medical oncologist counterparts. Lack of familiarity with Xtandi and because many eligible patients are already receiving Zytiga (Johnson & Johnson/Janssen Biotech/Janssen Cilag's abiraterone) are key reasons cited by surveyed respondents for not having prescribed Xtandi yet. However, the majority of current non-prescribing urologists (61 percent) and medical oncologists (88 percent) surveyed tell us that they expect to prescribe Xtandi within the next six months.

The findings also reveal that if Xtandi successfully secures a first-line label extension for use in chemotherapy-naive, asymptomatic or minimally symptomatic mCRPC, surveyed medical oncologists and urologists would prescribe it to nearly half of their eligible patients. Surveyed respondents' estimates of Xtandi's patient share in this patient population exceeds their current estimates of patient share for any other currently prescribed therapy in this setting, including Zytiga, exemplifying surveyed physicians' enthusiasm for this agent and eagerness to use it earlier in the mCRPC treatment algorithm.

"Xtandi is experiencing rapid uptake within its FDA-approved indication for docetaxel-pretreated mCRPC, and its inclusion on National Comprehensive Cancer Network guidelines for use in chemotherapy-naive, asymptomatic mCRPC patients who are not candidates for docetaxel is spurring its use in this earlier disease setting," said Decision Resources Group Senior Director of Oncology Rachel Webster , D.Phil. "While more than half of surveyed physicians report decreased use of Jevtana (Sanofi's cabazitaxel) in their docetaxel pretreated mCRPC patients, more than half of surveyed respondents currently report no change in their use of Zytiga in this setting."

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit www.bio-trends.com. BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com


'/>"/>
SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. At Three Months Post Launch, Two-Thirds of Surveyed U.S. Rheumatologists Believe that Initiations of Pfizers Xeljanz in the Rheumatoid Arthritis Treatment Algorithm Will Occur Following at Least Two Biologic Failures
2. New Obesity Education Program To Premiere At American College of Physicians (ACP) Annual Meeting
3. Physicians for Peace Resource Mothers Program Receives Sweatshirt Blanket Donation
4. Physicians for Peace Receives Logo Embroidered Polo Shirt Donation
5. Texas Fertility Center Introduces Oncofertility Education Program for Physicians and Patients
6. Physicians Endoscopy and Colon Cancer Challenge Foundation Partner to Raise Colon Cancer Awareness
7. Physicians for Peace Resource Mothers Program Receives Fleece Blanket Donation
8. Elsevier Launches PracticeUpdate, a Free Information Portal for Physicians
9. Douglas Harrington, MD Addresses Select Group Of Physicians Regarding Latest Advances In Cardiovascular Risk Assessment
10. Physicians for Peace Receives Logo Embroidered Lab Coat Donation from Crooked Brook
11. Four Texas Fertility Center Physicians Chosen as Super Doctors®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... ... proud to announce it has become the premiere team-building cooking event company in San Diego. ... such as Illumina, HP and Qualcomm, and is ranked #1 in its category on Trip ... its new team building format, a way for teams to not only interact with one ...
(Date:3/23/2017)... Calif., March 23, 2017  BioPharmX Corporation (NYSE ... for the dermatology market, today reported financial results ... 2017, and will provide an update on the ... year. "We are pleased to report ... for BioPharmX," said President Anja Krammer. "We achieved ...
(Date:3/23/2017)... , March 23, 2017  Agriculture technology company ... A financing and note conversion to commercialize its Cool ... is focused on developing products that are simultaneously profitable ... million in the last 18 months. This latest round ... Bridge Venture Partners. The company,s primary ...
(Date:3/22/2017)... 22, 2017  Ascendis Pharma A/S (Nasdaq: ASND), ... technology to address significant unmet medical needs in ... full year ended December 31, 2016. ... company as we broadened our pipeline and pursued ... disease company with an initial focus on endocrinology," ...
Breaking Biology Technology:
(Date:2/28/2017)... DORTMUND, Germany , February 28, 2017 ... ... Amsterdam from 14 to 16 March, ... to destination, and show how seamless travel is a real benefit ... Materna has added biometrics to their passenger touch point solutions to ...
(Date:2/27/2017)... , Feb. 27, 2017   Strategic Cyber ... announced it has led a $3.5 million investment in  ... platform. Strategic Cyber Ventures is DC based and is ... Hank Thomas . Ron Gula , also ... Ventures, also participated in this series A round of ...
(Date:2/24/2017)...  EyeLock LLC, a leader of iris-based identity ... biometric solution on the latest Qualcomm® Snapdragon™ 835 ... World Congress 2017 (February 27 – March ... 3, Stand 3E10. The Snapdragon ... platform—a combination of hardware, software and biometrics ...
Breaking Biology News(10 mins):